摘要
目的探讨不同类型生长激素治疗方案对特发性矮身材(idiopathic short stature,ISS)患儿的疗效、安全性及依从性。方法选取2021年3月至2024年3月在海宁市人民医院就诊的67例ISS患儿作为研究对象。依据生长激素治疗方案,将患儿分为长效组(n=16)、长转短组(n=14)和短效组(n=37)。长效组全程使用聚乙二醇重组人生长激素(polyethylene glycol recombinant human growth hormone,PEG-rhGH),长转短组初期使用PEG-rhGH后改用短效重组人生长激素(recombinant human growth hormone,rhGH),短效组全程使用rhGH。比较三组患儿治疗前及治疗3、6、9个月后的生长指标及安全性指标。结果长转短组患儿治疗3、6、9个月时的胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)水平均显著高于其他两组(P<0.05)。长效组、长转短组、短效组患儿的漏针率分别为0、7.1%、34.3%,短效组漏针次数显著高于长效组(Z=4.47,P<0.001)。结论三种生长激素治疗方案在ISS患儿中的疗效和安全性相当。长转短组依从性较好,剂型转换后需密切监测IGF-1水平。
Objective To evaluate the efficacy,safety,and adherence of different growth hormone treatment regimens in children with idiopathic short stature(ISS).Methods A total of 67 children with ISS who were treated at Haining People’s Hospital from March 2021 to March 2024 were selected as the study subjects.According to the growth hormone treatment protocol,the children were divided into three groups:Long-acting group(n=16),long-to-short group(n=14),and short-acting group(n=37).The long-acting group received polyethylene glycol recombinant human growth hormone(PEG-rhGH)throughout the treatment course,and long-to-short group initially used PEG-rhGH and then switched to short-acting recombinant human growth hormone(rhGH),and short-acting group received rhGH throughout the treatment.The growth indicators and safety indicators were compared before treatment and at 3,6,and 9 months post-treatment in all three groups.Results The insulin-like growth factor-1(IGF-1)levels in long-a to short-acting group were significantly higher than those in other two groups at 3,6,and 9 months of treatment(P<0.05).The missed injection rates were 0,7.1%,and 34.3%in long-acting group,long-a to short-acting group,and short-acting group,respectively.The short-acting group had significantly higher missed injection rates than long-acting group(Z=4.47,P<0.001).Conclusion The efficacy and safety of the three growth hormone treatment regimens were comparable in children with ISS.The long-to-short regimen demonstrated better adherence,and close monitoring of IGF-1 levels was required after formulation conversion.
作者
沈群华
於敏
SHEN Qunhua;YU Min(Department of Pediatrics,Haining People’s Hospital,Jiaxing 314400,Zhejiang,China)
出处
《中国现代医生》
2026年第2期59-63,共5页
China Modern Doctor
关键词
重组人生长激素
特发性矮身材
安全性
依从性
Recombinant human growth hormone
Idiopathic short stature
Safety
Efficacy
